The items were successfully added to the cart.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more


Reduced secretion of GLP-1 has been found in non-diabetic NAFLD and NASH patients with impaired insulin release1 and a reduced incretin effect has been suggested to be an early sign of impaired glucose tolerance, associated with IR and obesity2.
Incretin-based therapy has proven to have an effect on liver enzymes like ALT, reduces the hepatic lipid content and improves other hepatic functional markers3.

Liraglutide does not interfere in the Mercodia Total GLP-1 NL-ELISA which means that the ELISA assay is suitable for GLP-1 measurements even in samples from patients undergoing analogue treatment.  

  1. Bernsmeier, C. et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 9, e87488 (2014).
  2. Junker, A. E., Gluud, L., Holst, J. J., Knop, F. K. & Vilsbøll, T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J. Intern. Med. 279, 485–93 (2016).
  3. Carbone, L. J., Angus, P. W. & Yeomans, N. D. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 31, 23–31 (2016).